Related Experiment Videos

Patient adherence and preference considerations in managing cardiovascular risk: focus on single pill and

Farhan Aslam1, Attiya Haque, Veronica Lee

  • 1Division of Cardiovascular Medicine, Brigham and Women's Hospital, Boston, MA, USA.

Patient Preference and Adherence
|November 26, 2009
PubMed

Insights

Managing cardiovascular disease (CVD) risk factors like hypertension and dyslipidemia is crucial. A fixed-dose combination pill of amlodipine/atorvastatin can improve patient adherence and outcomes by simplifying treatment regimens.

Area of Science:

  • Cardiology
  • Pharmacology
  • Public Health

Background:

  • Cardiovascular disease (CVD) causes over 930,000 deaths annually in the US.
  • Hypertension and dyslipidemia frequently co-exist, with less than 10% of patients meeting therapeutic targets for both.
  • Non-adherence to complex medication regimens is a significant barrier to managing CVD risk factors.

Purpose of the Study:

  • To evaluate the fixed-dose combination of amlodipine/atorvastatin for managing co-existing hypertension and dyslipidemia.
  • To assess the potential of this combination therapy to improve patient adherence and clinical outcomes.

Main Methods:

  • The study focuses on the pharmacological properties and clinical application of the amlodipine/atorvastatin fixed-dose combination.
  • Observational data and clinical considerations regarding adherence and poly-pharmacy are discussed.

Main Results:

  • The fixed-dose combination of amlodipine/atorvastatin provides a synergistic effect for managing hypertension and dyslipidemia.
  • Its once-daily dosing, flexible administration (with or without food), and reduced pill burden enhance patient adherence.
  • This combination can be used for initiating therapy or switching from monotherapy.

Conclusions:

  • The single-pill amlodipine/atorvastatin offers a convenient and effective approach to managing key CVD risk factors.
  • Improved adherence through this fixed-dose combination has the potential to enhance cardiovascular risk management and clinical outcomes in selected patients.

Keywords:
adherenceamlodipine/atorvastatincardiovascular diseasedrug combinationpoly-pharmacy

Related Concept Videos

Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
Lipid-Lowering Drugs: Statins and Miscellaneous Agents01:20

Lipid-Lowering Drugs: Statins and Miscellaneous Agents

Hyperlipidemia, a medical condition often referred to as high cholesterol, is characterized by abnormally elevated levels of lipids in the bloodstream. When present in excess, these lipids, specifically cholesterol and triglycerides, can lead to serious health complications, often involving cardiovascular diseases. Illnesses like atherosclerosis, heart attacks, and pancreatitis have all been linked to untreated hyperlipidemia. This means controlling and regulating cholesterol and triglyceride...
Antianginal Drugs: Calcium Channel Blockers and Ranolazine01:25

Antianginal Drugs: Calcium Channel Blockers and Ranolazine

Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
Coronary Artery Disease V: Interprofessional Care01:27

Coronary Artery Disease V: Interprofessional Care

Interprofessional care for coronary artery disease includes pharmacological therapy and revascularization procedures.Pharmacological therapy for Coronary Artery Disease (CAD) aims to manage symptoms, prevent complications, and improve patient outcomes through various classes of medications:Antiplatelet Agents:Aspirin and Clopidogrel: These medications inhibit platelet aggregation, preventing blood clots, which is crucial for avoiding heart attacks and strokes. Doctors often prescribe these...
Angina IV: Management01:26

Angina IV: Management

IntroductionThe management of angina requires a comprehensive approach that includes pharmacological therapies, medical procedures, and lifestyle modifications.Pharmacological TherapiesAntiplatelet agents, such as aspirin, clopidogrel, prasugrel, and ticagrelor, play a pivotal role in preventing thrombus formation in patients with angina. These medications inhibit platelet aggregation and reduce the likelihood of myocardial infarction and other cardiovascular events.Anticoagulants, including...
Hypertension IV: Drug Therapy and Lifestyle Modifications01:28

Hypertension IV: Drug Therapy and Lifestyle Modifications

Multiple classes of antihypertensive medications are employed in treating hypertension. The most commonly recommended first-line treatments include:Thiazide Diuretics, such as chlorthalidone, increase sodium and water excretion from the body, reducing blood volume and blood pressure.Angiotensin-converting enzyme inhibitors, like lisinopril, block the conversion of angiotensin I to II, a potent vasoconstrictor lowering blood pressure.Angiotensin II Receptor Blockers (ARBs) prevent angiotensin II...